Medical fraud and arrogance have now failed Alzheimer’s sufferers
LONDON: Progress towards a cure for Alzheimer’s disease has been painfully slow. Billions have been spent trying to tackle a relentlessly cruel illness that counts among the UK’s leading causes of death.
The brain’s inherent complexity is part of the problem. How the interactions of its billions of neurons give rise to memory, agency and consciousness are still barely understood. But in Doctored, a rigorous and sobering new book, the journalist Charles Piller argues that another more sinister factor has also played a part: “decades of arrogance, greed, fabulism and error that has emptied research coffers and littered the drug development landscape with failure after failure”.
Piller specialises in investigative stories. He works for Science, one of the world’s top journals. It’s safe to say that if you’re a researcher engaged in dubious practices, his is one of the last voices you would want to hear on the other end of the phone. Here he provides a glimpse of how he goes about his trade — meticulously — and describes numerous cases of apparent scientific fraud, some involving influential Alzheimer’s work that may, Piller suggests, have misdirected the hunt for treatments.
At the core of the book is the dominant idea of what causes the disease: the “amyloid hypothesis”. It argues that Alzheimer’s and its symptoms — forgetfulness, confusion, hallucinations, loss of speech and so on — are driven by the accumulation of two hallmark proteins. First there’s amyloid, a sticky substance that gathers into small groups called oligomers that then group further into large, sticky clumps known as “plaques” on the surface of brain cells. The second protein, known as tau, forms misshapen “tangles” inside neurons.
The amyloid hypothesis has held sway for decades. By the mid-2000s, the Harvard professor Dennis Selkoe, a prominent advocate, was the most cited researcher in the field. But doubts were also beginning to emerge, not least because post-mortem investigations found massive amyloid and tau deposits in the brains of people who had died at old ages with no signs of dementia and no cognitive decline. Could the build-up of amyloid and tau be a symptom rather than a cause? Were researchers with competing ideas being sidelined by an “amyloid mafia” of invested senior scientists?
As Piller tells it, a study emerged at a critical moment to bolster the hypothesis. Published in 2006, it came from the laboratory of Karen Ashe, a professor at the department of neurology and neuroscience at the University of Minnesota, and her protégé, the French neuroscientist Sylvain Lesne. It described what appeared to be a landmark experiment. They reported that they had found a specific type of amyloid — known as Aβ*56 (“amyloid beta star 56”) — in mice genetically engineered to develop an Alzheimer’s-like condition, and that it accumulated in step with their cognitive decline. They also reported that when rats were injected with Aβ*56, they developed memory problems.
In a blog post, Ashe claimed to have found “the first substance ever identified in brain tissue in Alzheimer’s research that has been shown to cause memory impairment”. On Alzforum, an online meeting place for researchers, one contributor marvelled at how she had “already determined that patients with Alzheimer’s have detectable amounts of Aβ*56, which people without AD did not”. The paper was cited by other groups nearly 2,500 times, making it one of the most influential in the field.
Then in 2022, Piller — who was aided in his work by Matthew Schrag, a neuroscientist and physician at Vanderbilt University — published a bombshell article in Science that alleged the key test results in the Ashe paper had been doctored. Ashe has maintained that “the manipulations did not change the conclusions of the experiments”. But in June last year her paper was retracted. Others, including one where it was claimed levels of Aβ*56 climbed as people aged, have been corrected. Rival scientists, newly emboldened, have described never being able actually to find Aβ*56 in human tissue samples.
It is not the only research that Piller has exposed as shaky. There’s also the case of Eliezer Masliah, who in 2016 was asked to lead a flagship US government push to tackle Alzheimer’s. “With roughly 800 papers to his name, many of them considered highly influential, Dr Masliah seemed a natural choice to steer the project,” Piller writes. He was entrusted with billions in new funding.
Last September in Science, Piller presented evidence that for decades Masliah’s research had included improperly manipulated photos of brain tissue and was “riddled with apparently falsified Western blots — images used to show the presence of proteins”. Masliah has been approached for comment by The Times.
Piller also looks at the biopharma company Cassava Sciences. In November it announced that an experimental Alzheimer’s drug it had developed, called simufilam, showed no signs of working in a phase 3 clinical trial. It was the death rattle of a treatment that had long been controversial. In 2021 a law firm representing two whistleblowers, who stood to profit if Cassava’s stock fell, had filed a citizen’s petition with the US Food and Drug Administration (FDA). It alleged that studies that seemed to signal that it was worth pushing on to human testing included fraudulent images.
In 2023 Piller had revealed that one of the neuroscientists who had worked on the simufilam compound had been found by a university panel to have engaged in “egregious misconduct”. The scientist was later indicted by the US Department of Justice for “defrauding the National Institutes of Health of approximately $16 million” in grants related to simufilam and Cassava. Last year the company agreed to pay $40 million to the Securities and Exchange Commission to settle charges that it had misled investors about earlier clinical trial results.
Why would scientists lie and cheat? For the same reasons as anybody else: for money and prestige. But there’s also the matter of the supremacy of the amyloid hypothesis. Its entrenchment “has fostered a kind of groupthink where grants, corporate riches, career advancement and professional reputations often depend on a central idea largely accepted by institutional authorities on faith”, Piller says. It is much easier, he notes, to publish junk results that align with a flawed consensus than it is to upend prevailing ideas.
Piller has a point. Scientists have created drugs that are marvellously efficient in mopping up amyloid from the brain. But these treatments haven’t shown any sign of reversing Alzheimer’s. The most promising trials have produced results that have suggested a modest slowing of the disease. But some experts have warned that the effects are so mild, patients and their caregivers are often unlikely to discern them. Moreover, these drugs can carry serious side-effects, including one known as “Aria”. The term stands for “amyloid related imaging abnormalities”. As Piller says, it’s a nicely sanitised term for a condition that involves bleeding of the brain and can be fatal.
One treatment, the anti-amyloid drug aducanumab, was billed as a blockbuster in waiting. It was withdrawn last year after generating next to no revenue in the US, where clinicians declined to prescribe it and insurers refused to cover its initial $56,000-per-patient annual cost. That it was approved in the US may stand testament to the sheer force of the amyloid hypothesis. But over the longer term, biology couldn’t be duped.
As one of Piller’s sources says, you can’t con a disease.






